Top 3 novel diabetes treatmentsOver the past few months, several new diabetes treatments have been approved by FDA. Here are the top 3 novel drugs for diabetes.
The OD’s role with new diabetes drugsIt is important for eyecare providers to be familiar with these new drugs and findings. We often see patients with diabetes, metabolic syndrome, and high CV risk, and we are in a position to help counsel our patients about new treatments—and even suggest that appropriate patients have conversations with their primary-care physicians, endocrinologists and cardiologists.
FDA should pull diabetes drug ads, group saysConsumer advocacy group Public Citizen said this week that the Food and Drug Administration (FDA) must stop direct-to-consumer advertisements that market several “dangerous” diabetes medications for weight loss or blood pressure reduction.
GLP-1 targeted therapy may help diabetes patientsThe role of ophthalmologists will become increasingly more vital in the management of type 2 diabetes as the numbers of patients with the disease is projected to double by 2030. Exenatide may prove to be an important adjunct to current oral anti-diabetes drugs.
FDA approves first once-weekly pen for diabetesBringing a new tool to the arsenal of medications to treat type 2 diabetes, FDA recently approved the only once-weekly injectable pen for adults with type 2 diabetes.
FDA: FDA approvals March 7FDA drug approvals for the week ending March 7